Applied radiomics pioneer, HealthMyne and Flywheel, a leading cloud-scale informatics platform for medical research and collaboration, announced a partnership that will accelerate radiomics research and improve clinical trials outcomes for life sciences and clinical research clients.
According to Rose Higgins, CEO, HealthMyne, “Leveraging Flywheel’s bioinformatics platform coupled with HealthMyne’s ability to compute advanced imaging analytics and reveal radiomic insights further enhances the understanding of disease progression, treatment response, and clinical trial outcomes. This partnership will enable our clients to fully realize the value of their imaging pipeline to help tackle complex diseases such as cancer.”
Together, HealthMyne’s radiomics solutions and Flywheel’s comprehensive informatics platform offer an innovative approach to clinical trials and research. Through the use of open, extensible platforms, it is possible to automate and streamline data curation, quantitative image analysis, and radiomic computation.
The Flywheel platform helps life sciences, clinical, and academic researchers transform productivity, curation, and collaboration with medical research data. As part of its solution, HealthMyne performs radiomic analysis, which is the process of converting quantitative descriptors of tumor structure and lesion characteristics into usable data to develop new therapeutic approaches and assessment methods.
Jim Olson, the CEO, Flywheel, said, “By combining medical imaging and genomics data on a single cloud-scalable platform, researchers can now enter uncharted territory in healthcare innovation – streamlined, enterprise-scale radiomics research. HealthMyne’s innovative algorithms on Flywheel’s platform will not only provide valuable insights in clinical trials but also accelerate the development of new discoveries in cancer research.”
With these combined technologies, life science companies and researchers can gain a deeper understanding of tumor or lesion response to specific treatments, offer new insights into clinical trials, and use novel data to personalize treatments for the most effective outcomes.
